[go: up one dir, main page]

UY26209A1 - ANTAGONISTS OF THE RECEIVERS OF THE IL-8. - Google Patents

ANTAGONISTS OF THE RECEIVERS OF THE IL-8.

Info

Publication number
UY26209A1
UY26209A1 UY26209A UY26209A UY26209A1 UY 26209 A1 UY26209 A1 UY 26209A1 UY 26209 A UY26209 A UY 26209A UY 26209 A UY26209 A UY 26209A UY 26209 A1 UY26209 A1 UY 26209A1
Authority
UY
Uruguay
Prior art keywords
antagonists
receivers
interleukin
formula
treatment
Prior art date
Application number
UY26209A
Other languages
Spanish (es)
Inventor
Bryan
Gleason
Widdowson
Benson
Original Assignee
Smithkline Beecham Corporetion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporetion filed Critical Smithkline Beecham Corporetion
Publication of UY26209A1 publication Critical patent/UY26209A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a nuevos compuestos de la fórmula (I), a composiciones farmacéuticas, y a su uso en el tratamiento de enfermedades mediadas por la quimioquina interleuquina-8 (IL-8).This invention relates to novel compounds of formula (I), to pharmaceutical compositions, and to their use in the treatment of interleukin-8 (IL-8) chemokine mediated diseases.

UY26209A 1999-06-16 2000-06-14 ANTAGONISTS OF THE RECEIVERS OF THE IL-8. UY26209A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
UY26209A1 true UY26209A1 (en) 2000-12-29

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26209A UY26209A1 (en) 1999-06-16 2000-06-14 ANTAGONISTS OF THE RECEIVERS OF THE IL-8.

Country Status (22)

Country Link
EP (1) EP1191934A4 (en)
JP (1) JP2003501471A (en)
KR (1) KR20020009635A (en)
CN (1) CN1494424A (en)
AR (1) AR029368A1 (en)
AU (1) AU766086B2 (en)
BR (1) BR0010985A (en)
CA (1) CA2377397A1 (en)
CZ (1) CZ20014490A3 (en)
EC (2) ECSP003525A (en)
HK (1) HK1044716A1 (en)
HU (1) HUP0202019A3 (en)
IL (1) IL146214A0 (en)
MX (1) MXPA01013287A (en)
NO (1) NO20016065D0 (en)
NZ (1) NZ515232A (en)
PE (1) PE20010319A1 (en)
PL (1) PL352218A1 (en)
TR (1) TR200103690T2 (en)
UY (1) UY26209A1 (en)
WO (1) WO2000076516A1 (en)
ZA (1) ZA200110203B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344425B1 (en) * 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.

Also Published As

Publication number Publication date
NO20016065L (en) 2001-12-12
MXPA01013287A (en) 2002-06-04
CA2377397A1 (en) 2000-12-21
JP2003501471A (en) 2003-01-14
EP1191934A1 (en) 2002-04-03
AU5748200A (en) 2001-01-02
ECSP003525A (en) 2002-01-25
IL146214A0 (en) 2002-07-25
HUP0202019A2 (en) 2002-10-28
AR029368A1 (en) 2003-06-25
TR200103690T2 (en) 2002-05-21
EP1191934A4 (en) 2004-02-04
AU766086B2 (en) 2003-10-09
KR20020009635A (en) 2002-02-01
HUP0202019A3 (en) 2003-03-28
ECSP003528A (en) 2002-01-25
ZA200110203B (en) 2002-09-11
BR0010985A (en) 2002-03-26
PL352218A1 (en) 2003-08-11
NO20016065D0 (en) 2001-12-12
WO2000076516A1 (en) 2000-12-21
PE20010319A1 (en) 2001-05-24
NZ515232A (en) 2004-02-27
CN1494424A (en) 2004-05-05
HK1044716A1 (en) 2002-11-01
CZ20014490A3 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
TR199900318T2 (en) IL-8 receptor antagonists.
BG66084B1 (en) Cyclopentanoindoles, compositions containing such compounds and their use
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
UY28766A1 (en) ADDITIONAL HETEROPOLYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER
ATE293448T1 (en) BENZO(D)AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS
DE60230722D1 (en) IL-8 RECEPTOR ANTAGONISTS
HN2002000365A (en) LACTAMAS AS TAQUIQUININE ANTAGONISTS
PA8579601A1 (en) ANTIINFLAMMATORY COMPOUNDS OF DI AND TRIFLORURO-TRIAZOLO-PIRIDINAS
UY26601A1 (en) IL-8 RECEPTOR ANTAGONISTS
SE9902765D0 (en) Novel compounds
BR9909486A (en) Calcilic compounds
SE9901077D0 (en) Novel use
SE0302304D0 (en) Novel compounds
WO2001068568A3 (en) Il-8 receptor antagonists
SE9801494D0 (en) Novel use
NZ514696A (en) IL-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
BR0010843A (en) Il-8 receptor antagonists
WO2001068569A3 (en) Il-8 receptor antagonists
PT1497292E (en) AZAINDOLILPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALERGIC AGENTS
BR0010863A (en) Il-8 receptor antagonists
UY26209A1 (en) ANTAGONISTS OF THE RECEIVERS OF THE IL-8.
AP2002002606A0 (en) IL-8 receptor antagonists.
ECSP003527A (en) IL RECEIVER ANTAGONISTS - 8 V
WO2004039775A3 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100520